203 related articles for article (PubMed ID: 28737125)
1. Taxanes in combination with platinum derivatives for the treatment of ovarian cancer during pregnancy: A literature review
.
Zheng X; Zhu Y; Zhao Y; Feng S; Zheng C
Int J Clin Pharmacol Ther; 2017 Sep; 55(9):753-760. PubMed ID: 28737125
[TBL] [Abstract][Full Text] [Related]
2. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
3. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors.
Brown J; Shvartsman HS; Deavers MT; Ramondetta LM; Burke TW; Munsell MF; Gershenson DM
Gynecol Oncol; 2005 May; 97(2):489-96. PubMed ID: 15863149
[TBL] [Abstract][Full Text] [Related]
4. Current status of taxane and platinum-based chemotherapy in ovarian cancer.
McGuire WP
J Clin Oncol; 2003 May; 21(10 Suppl):133s-135s. PubMed ID: 12743128
[TBL] [Abstract][Full Text] [Related]
5. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines.
Smith JA; Ngo H; Martin MC; Wolf JK
Gynecol Oncol; 2005 Jul; 98(1):141-5. PubMed ID: 15963813
[TBL] [Abstract][Full Text] [Related]
7. Taxanes during pregnancy in cervical cancer: A systematic review and pooled analysis.
Zagouri F; Korakiti AM; Zakopoulou R; Kyriazoglou A; Zografos E; Haidopoulos D; Apostolidou K; Papatheodoridi MA; Dimopoulos MA
Cancer Treat Rev; 2019 Sep; 79():101885. PubMed ID: 31442939
[TBL] [Abstract][Full Text] [Related]
8. Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience.
Leiser AL; Chi DS; Ishill NM; Tew WP
Gynecol Oncol; 2007 Jun; 105(3):657-61. PubMed ID: 17395252
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of neoadjuvant platinum-based chemotherapy during the second and third trimester of pregnancy in women with cervical cancer: an updated systematic review and meta-analysis.
Song Y; Liu Y; Lin M; Sheng B; Zhu X
Drug Des Devel Ther; 2019; 13():79-102. PubMed ID: 30587930
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel: an alternative taxane in ovarian cancer.
Katsumata N
Br J Cancer; 2003 Dec; 89 Suppl 3(Suppl 3):S9-S15. PubMed ID: 14661041
[TBL] [Abstract][Full Text] [Related]
11. Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer.
Vasey PA
J Clin Oncol; 2003 May; 21(10 Suppl):136s-144s. PubMed ID: 12743129
[TBL] [Abstract][Full Text] [Related]
12. Taxanes for ovarian cancer during pregnancy: a systematic review.
Zagouri F; Sergentanis TN; Chrysikos D; Filipits M; Bartsch R
Oncology; 2012; 83(4):234-8. PubMed ID: 22907101
[TBL] [Abstract][Full Text] [Related]
13. The fetal outcomes after neoadjuvant platinum and paclitaxel chemotherapy during pregnancy: analysis of three cases and review of the literature.
Wang M; Yin Z; Miao J; Wu Y
Arch Gynecol Obstet; 2022 Jan; 305(1):49-54. PubMed ID: 34115181
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas.
Matsuo K; Eno ML; Im DD; Rosenshein NB
Arch Gynecol Obstet; 2010 Feb; 281(2):325-8. PubMed ID: 19455347
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
16. Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer.
Muggia FM
Semin Oncol; 2004 Dec; 31(6 Suppl 15):19-24. PubMed ID: 15726535
[TBL] [Abstract][Full Text] [Related]
17. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
18. Platinum derivatives during pregnancy in cervical cancer: a systematic review and meta-analysis.
Zagouri F; Sergentanis TN; Chrysikos D; Bartsch R
Obstet Gynecol; 2013 Feb; 121(2 Pt 1):337-343. PubMed ID: 23344284
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship.
Stordal B; Pavlakis N; Davey R
Cancer Treat Rev; 2007 Dec; 33(8):688-703. PubMed ID: 17881133
[TBL] [Abstract][Full Text] [Related]
20. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
Matsuo K; Bond VK; Eno ML; Im DD; Rosenshein NB
Int J Cancer; 2009 Dec; 125(11):2721-7. PubMed ID: 19530239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
